Street Calls of the Week
Bolt Biotherapeutics, Inc., a pharmaceutical company specializing in the development of immuno-oncology drugs, announced significant changes to its board of directors. The company, based in Redwood (NYSE:RWT) City, California, disclosed the departure of two board members and the appointment of a new one in a recent 8-K filing.
On August 28, 2024, James Healy, M.D., Ph.D., informed the company of his decision to resign from the board and its committees, effective September 3, 2024. Similarly, Frank D. Lee announced his resignation on September 1, 2024, also effective as of September 3, 2024. Both departures are reportedly not due to any disagreements with the company's operations, policies, or practices.
In the wake of these departures, Bolt Biotherapeutics has appointed Jakob Dupont, M.D., Ph.D., as a Class II member of the board, effective September 3, 2024. Dr. Dupont, 59, brings extensive experience in the pharmaceutical industry, having served in leadership roles at several biotech firms, including Atara Biotherapeutics (NASDAQ:ATRA), Gossamer Bio (NASDAQ:GOSS), and Genentech. His term on Bolt's board will extend until the company's 2026 annual meeting of stockholders.
Dr. Dupont's appointment aligns with the company's non-employee director compensation policy, and he will receive remuneration consistent with other non-employee directors. Further details about his compensation were outlined in the proxy statement filed with the Securities and Exchange Commission on April 26, 2024.
In other recent news, Bolt Biotherapeutics, a clinical-stage biopharmaceutical company, has undergone significant changes in its Board of Directors. Jakob Dupont, M.D., with a robust background in oncology and immuno-oncology, has been appointed to the board, while Dr. Jim Healy and Frank D. Lee have departed.
Brian O'Callaghan, CEO of Deep Genomics, has assumed the role of Chair. This reshuffling coincides with Bolt's ongoing clinical trial of BDC-3042, a first-in-class Dectin-2 agonist, and the development of a near-clinical ISAC program targeting Claudin 18.2.
Bolt Biotherapeutics is also dealing with a potential delisting risk from the Nasdaq Stock Market due to non-compliance with the exchange's minimum bid price requirement. The company has been given a 180-day grace period to regain compliance. If necessary, Bolt Biotherapeutics may consider implementing measures such as a reverse stock split to meet the requirements.
Furthermore, Bolt Biotherapeutics is facing significant changes following the discontinuation of its leading drug candidate, BDC-1001, and the departure of its CEO and CMO. These developments led Guggenheim Securities to downgrade the company's stock from Buy to Neutral. The firm also noted the reduction of half of Bolt's workforce.
Despite these challenges, Bolt Biotherapeutics still has two other drug candidates, BDC-3042 and BDC-4182, in the pipeline. However, Guggenheim expressed concerns about the potential success of these remaining candidates due to their "low visibility" of achieving positive outcomes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.